CURX — Q2 2026 Financial Report Analysis

Curanex Pharmaceuticals is a small, pre-revenue drug developer based in Jericho, New York. It is trying to turn Phyto-N, an extract of a medicinal plant used in traditional Chinese medicine, into an FDA-approved botanical drug, starting with ulcerative colitis (a chronic inflammatory bowel disease). It has not tested Phyto-N in people yet. In the second quarter of 2026 (April to June) it again had no revenue and lost $3.29 million, against $60,346 a year earlier, when it was still a private company spending almost nothing. Nearly all of the increase is the animal-safety and manufacturing work the FDA requires before human trials, paid for with the roughly $15.3 million it raised in its August 2025 IPO. That money is now running low: cash fell to $2.94 million, and the company says it does not have enough to fund the next 12 months.

At a glance

• $2.59 million of research and development (R&D) spending in the quarter, 78% of all costs. It went on safety studies in rats and dogs and on drug-manufacturing work needed for an "IND", the application that asks the FDA for permission to start human trials. Curanex is targeting a fourth-quarter 2026 filing.
• $2.94 million of cash at June 30, down from $4.97 million at the end of 2025. Cash fell only $2.03 million in six months because $4.35 million of the work had been paid for in advance last year. The company says that cushion is nearly used up and its cash spending will now rise to roughly match its costs.
• A "going concern" warning, a 1-for-20 reverse stock split, and 3 million new shares. The company states there is substantial doubt it can keep operating without new money. After quarter-end it issued 3,000,000 shares from its new staff stock plan (about 10.6% more shares) and combined every 20 shares into one on August 20, 2026, which lifted the price back above Nasdaq's $1 minimum.

Second quarter 2026 in figures

"n/m" means not meaningful: a year ago the company was private and had almost no spending, so percentage changes would be huge and say little.

For context, the first quarter of 2026 had a net loss of $3.15 million, so spending is still creeping up: R&D rose from about $2.26 million in Q1 to $2.59 million in Q2 (+15%). Over the first half, the net loss was $6.44 million, against $197,929 in the first half of 2025.

Where the money went

Research and development ($2.59 million in the quarter, $4.85 million for the half). The filing ties this to "FDA-mandated investigational new drug (IND) studies," led by ulcerative colitis and, since April 2026, cancer cachexia (the severe weight and muscle loss many advanced cancer patients suffer), plus earlier-stage work in atopic dermatitis (eczema), rheumatoid arthritis, gouty arthritis and diabetic foot. Most of it is paid to outside contract labs and manufacturers. What it bought so far:

• February 2026: a first pilot batch of Phyto-N made to GMP standards (the manufacturing-quality rules a drug must meet before it can be given to people).
• March 2026: a 28-day dose-range study in rats and dogs, used to pick doses for the formal safety studies.
• Now under way: the formal GLP (laboratory-quality standard) repeat-dose toxicology studies in rats and dogs, and safety studies of the heart, nervous system and breathing. These are core parts of the IND.

General and administrative ($0.73 million vs. $0.06 million). The company attributes the jump mainly to about $348,072 more in payroll, because the founder and senior managers began drawing pay after the IPO, plus the legal, audit and listing costs of being a public company.

Other income ($34,590) is interest earned on the IPO cash. It will shrink as the cash does.

What the headline numbers hide

• The cash burn looks lighter than the real spending rate. In the first half the company recorded $6.51 million of operating costs but spent only $2.03 million in cash. The gap is prepaid R&D: Curanex paid contract labs in advance in 2025, and those prepayments fell from $6.17 million to $1.82 million as the work was done. Management says that "as these prepaid balances are consumed," cash used in operations will "increase substantially and approximate our operating expenses." At the Q2 cost rate of about $3.3 million a quarter, $2.94 million of cash covers less than one quarter of spending. Even counting the $1.82 million of already-paid work, cash plus prepaid totals $4.79 million, roughly 1.4 quarters at that rate. That is our own arithmetic, not a company forecast, but it matches the company's statement that its cash will not last 12 months.
• No financing is lined up. The filing says the company has "no committed sources of additional capital and no available credit facility." Options it lists are selling shares or debt, partnerships or licensing deals, or cutting programs. Selling shares at today's market value would add significantly to the share count.
• Dilution has already started. Between July 27 and August 7, 2026, Curanex issued all 3,000,000 shares registered under its 2026 Equity Incentive Plan (a pool of shares used to pay staff, directors and consultants), adding about 10.6% to the 28.36 million shares outstanding. The plan reserves 5.7 million in total, so 2.7 million more could follow once registered. Because these shares were issued after June 30, any compensation expense from them will appear from the third quarter. It will not use cash, but it will widen the reported loss.
• The per-share loss will look much bigger next time, for a mechanical reason. The $(0.12) loss per share is calculated on the pre-split share count. After the 1-for-20 reverse split (about 31.4 million shares became about 1.57 million), the same Q2 loss works out to roughly $(2.32) per share. Nothing changed in the business; there are just 20 times fewer shares.
• No one-off items. There is no revenue, no impairment and no unusual gain distorting the quarter. The loss is simply the cost of running the studies and the company.

Takeaway: Curanex's science is moving on schedule toward a fourth-quarter 2026 IND, but its cash is not keeping pace. The low cash burn so far came from prepayments made last year. With $2.94 million left against roughly $3.3 million of quarterly costs and no financing in place, raising money, and diluting shareholders, is likely to come before any human-trial result.

What to watch

Management's timeline: a pre-IND meeting with the FDA in October 2026, an IND for ulcerative colitis in the fourth quarter of 2026, and, if the FDA does not object, a Phase I safety trial in healthy volunteers starting 30 days after the filing. Positive Phase I results would lead to a Phase II trial in ulcerative colitis patients. The filing notes that clinical trials "require substantial capital that we have not yet secured." So the two things that matter most in the third-quarter report (due around mid-November 2026) are whether the IND went in on time, and how the company will pay for Phase I: a share sale, a licensing partner, or cutting the secondary programs (cachexia, eczema, arthritis, diabetic foot) to stretch the cash.

The Nasdaq issue is resolved for now. Nasdaq confirmed on September 3, 2026 that the stock had closed at $1.00 or more for 10 straight trading days after the split. But a reverse split does not add any cash, and another equity raise would put pressure on the share price again. Our read: Curanex looks like a company with a plausible plan to reach the clinic, but without the money yet to run the trial. The next filing should show whether that gap gets closed, and how.